港股異動 | 永勝醫療(1612.HK)漲超27%創新高 暫三連升累漲約1.47倍
格隆匯7月6日丨永勝醫療(1612.HK)今日續漲,盤中高見2.8港元續創上市新高,現報2.67港元,大漲27.14%,暫成交6829萬港元,最新總市值17億港元。永勝醫療6月30日盤後發公告稱,集團的Inspired™熱濕交換過濾器("HMEF")及細菌/病毒呼吸過濾器,以及和普樂TM氣道正壓通氣治療機8系列("PAP 8系列")最近獲美國食品藥品監督管理局(" FDA ")授予緊急使用授權。公告發布後迄今,該股已連續三日大漲,現較公告當日收盤價1.08港元累漲約1.47倍。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.